50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)

Is it Time to Cash Out Novavax Stock?

Is it Time to Cash Out Novavax  Stock?

Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S. The U.S. FDA approval was granted on July 13th making it the fourth COVID-19 vaccine approved in the U.S., but still needs the CDC approval to begin marketing. The Company had its first profitable quarter in its history in fiscal Q1 2022. The market adage goes, “Buy the rumor and Sell the news” applies here. The COVID-19 pandemic skyrocketed Novavax stock from a low of $6.26 in February 2020 to a nosebleed high of $331.68 in February 2021. While most of the U.S. COVID vaccinations have been supplied through Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) or Johnson and Johnson (NYSE: JNJ), there is optimism for Nuvaxovid applications for people unable to tolerate mRNA technology.

Side Effects Hit Headlines

Recently the European Medicines Agency (EMA) indicated that severe allergic reactions will be added to the label as a side effect including paraesthesia and hypoaesthesia. The vaccines has a 90.4% efficacy rate according to its U.S. and Mexico trials. The Company may turn out to be a one-hit wonder as the FDA approval of Nuvaxovid marks it’s first in 35 years. Novavax has $20.11 cash-per-share and no long-term debt with a small 78 million share float with a 19% short interest. However, the race for a COVID-19 vaccines has already been won by the top three and there is very little indication of significant demand in the U.S. Investors expecting a return to its prior highs should reconsider utilizing opportunistic exit levels to cash out into strength.


Q1 Fiscal 2022 Earnings Release

On May 9, 2022, Novavax released its fiscal first-quarter 2022 results for the quarter ending March 2022. The Company reported an earnings-per-share (EPS) profit of $2.56 versus $2.49 consensus analyst estimates, a $0.07 beat. The Company saw revenues grow 57.4% year-over-year (YoY) to $703.97 million falling short of analyst estimates for $845.2 million. The Company reaffirms fiscal full-year 2022 revenue guidance for $4 billion to $5 billion compared to $4.49 billion analyst estimates. Novavax CEO Stanley Erck commented, "Novavax has been successful in launching our protein-based COVID-19 vaccine worldwide and executing on our plans for ongoing label expansions for pediatrics and homologous and heterologous boosting. Reinforced by our first profitable quarter, with $704 million in revenue, we are continuing our robust commercial rollout. Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-Influenza Combination vaccine candidate." 

It’s Time to Cash Out Novavax  Stock

NVAX Opportunistic Exit Levels

Using the rifle charts on the weekly and daily time frames provides a precision view of the landscape for NVAX stock. The weekly rifle chart bottomed at $37.37 and staged a rally as shares surged to a high of $76.77 ahead of the FDA approval news. Shares sold off and triggered a mini inverse pup breakdown on the rejection of the $73.91 Fibonacci (fib) level. The weekly uptrend has stalled with a 5-period moving average (MA) at $55.92 and 15-period MA at $52.92. The weekly 200-period MA resistance sits at the $84.60 fib. The weekly stochastic triggered a mini pup bounce through the 20-band but is stalling at the 40-band. The weekly market structure high (MSL) sell triggers on a breakdown under $47.68. The daily rifle chart is attempts to reverse and breakdown as the falling 5-period MA at $62.58 falls towards the 15-period MA at $60.47. The daily 50-period MA sits at $52.54. The daily stochastic has a mini inverse pup falling through the 80-band. The daily market structure low (MSL) buy triggered on the breakout through $39.50. The $20.11 price level is the cash per share floor. The daily lower Bollinger Bands (BBs) sit at $27.69. Investors can use opportunistic exit levels from the $60.37 level to the $84.60 level to trim or sell shares. The weekly MSH trigger at $47.68 can act as a trap door trigger for the stock price if it breaks. The $39.50 daily MSL trigger can be used as a stop-loss level. Seasoned and nimble traders can look for a bounce off the $20.10 cash per share floor level.

 

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
2.9959 of 5 stars
$44.43+0.8%3.60%8.69Moderate Buy$57.00
Moderna (MRNA)
2.7182 of 5 stars
$122.15-0.1%N/A3.72Hold$211.08
Johnson & Johnson (JNJ)
2.3327 of 5 stars
$166.36+0.9%2.72%24.22Moderate Buy$189.78
Novavax (NVAX)
2.527 of 5 stars
$19.61-2.1%N/A-1.01Hold$128.25
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Novavax right now?

Before you consider Novavax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.

While Novavax currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Jea Yu

About Jea Yu

Contributing Author: Trading Strategies

With over 20 years of active participation and analysis of the US equities, options and futures markets, Mr. Yu brings fresh insights into the workings of the financial markets. He has published four books by esteemed publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. His brainchild, the Underground Trader, was voted Forbes Best of the Web for four consecutive years under the active trader category. He has been a featured speaker all over the country at various expos and seminars who enjoys a standing-room-only reception in the largest convention halls from New York to Las Vegas. He has been quoted and featured in USA Today, Wall Street Journal, Traders Magazine and the Financial Times and various trade publications like Stocks & Commodities, Active Trader and Online Investor. Mr. Yu has a B.A. in Liberal Arts and minor in Business Administration from the University of Maryland.
Contact Jea Yu via email at JeaYu21@gmail.com.
Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC

Axel Merk, President and CIO of Merk Investments has three very different stocks he frames within the current market and economic conditions.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.